-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR): 'evolving into a platform-agnostic, CNS disease focused biotech'
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) PT Raised to $12 at Leerink Partners
-
-
-
-
-
-
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Provides Update on SOD1 ALS Gene Therapy Program
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR)
-
-
-
-
-
408,193 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

